

Pre-approval Information Exchange Act

The Pre-approval Information Exchange (PIE) Act of 2022 ([H.R. 7008](#)) has received its first co-sponsor! Congressman Morgan Griffith (R-VA-9) joined the bill on March 30. Securing co-sponsorship, effectively an endorsement of a bill and commitment to support it, is key to advancing legislative priorities. Following the March 17 User Fee Act Reauthorization hearing, the next benchmark for the PIE Act is inclusion in a May Energy & Commerce Health Subcommittee mark-up. Inclusion is not guaranteed, so please continue to [tell your Representatives](#) that you support the PIE Act.

Visit AMCP's [PIE Act resource center](#) to learn more.

GEMTESA
DISCOVER AN ALTERNATIVE FORMULARY OPTION

Find out more at [GEMTESA.com](#)



GEMTESA, and the GEMTESA logo are trademarks of Urovant Sciences GmbH, registered in the U.S. and in other countries.
© 2021 Urovant Sciences. All Rights Reserved. 6/21 US-VBGN-2000113 (v2.0)

New Member Benefit! Interactive State Policy Map

We are happy to announce the launch of the [interactive state policy map](#) as a new members-only benefit. With the ability to filter by state and issue area, you can now easily view state-level legislation that AMCP is tracking and monitoring. Never miss a new piece of legislation when AMCP's tracking software updates the state policy map daily. Locate the map on the "[Find Legislation](#)" page under the Policy & Advocacy dropdown menu.

ACCESS TODAY

Eye On Washington

Access to Prescription Digital Therapeutics Act

The Access to Prescription Digital Therapeutics Act of 2022 ([S. 3791](#)/[H.R. 7051](#)) has received two co-sponsors on the House version! Representatives Doris Matsui (D-CA-6) and Kevin Hern (R-OK-1) both joined the bill on April 5. One of AMCP's top federal priorities, this bill will authorize coverage of prescription digital therapeutics (PDTs) by the Medicare and Medicaid programs. PDTs are evidence-based treatments subject to review and approval by the Food & Drug Administration that use software to deliver a clinical benefit. The bill has not yet received any co-sponsors in the Senate, and more support is needed in the House to secure passage. Please continue to [reach out to your Members of Congress](#) to encourage them to support this important bill.

Visit AMCP's Access to Prescription Digital Therapeutics Act [resource center](#)

Advocacy Tip

Stay up-to-date: Read AMCP's [Letters, Statements and Analysis](#) on all legislation and regulation impacting managed care pharmacy.

to learn more.

CMS Finalizes Alzheimer's Drug Coverage Decision

On April 7, the Centers for Medicare & Medicaid Services (CMS) published its [final National Coverage Determination memo](#) for the class of anti-amyloid monoclonal antibody treatments indicated to treat Alzheimer's disease. At this time, Biogen's Aduhelm is the only approved therapy in this class. CMS elected to continue its Coverage with Evidence Development (CED) criteria, limiting coverage to Medicare beneficiaries enrolled in a qualifying clinical trial, citing concerns about safety and efficacy. However, the criteria for a qualifying trial were somewhat loosened in the final decision. Medicare acknowledged concerns about Medicaid costs by stating that Medicaid is prohibited by law from covering drugs covered by Medicare Parts B and D for dually eligible beneficiaries. Medicaid will only be responsible for coverage in patients enrolled only in Medicaid and may impose utilization management requirements.

Read [AMCP's comments](#) on the proposed decision in support of the CED criteria.

ICYMI: AMCP Policy & Government Relations Agenda Webinar

On April 7, AMCP's Policy & Government Relations team presented the organization's strategy to implement four key public policy priorities that will advance managed care pharmacy. This member-only webinar provides an overview of how the agenda will advance AMCP's Strategic Priorities and establish AMCP as a health policy thought leader. AMCP staff shared short- and long-term goals, investments, and tactics to promote biosimilars research, secure access to innovative digital therapies for Medicare and Medicaid beneficiaries, establish statutory protections for proactive communications between manufacturers and health care decision makers to speed patient access to new treatments, and promote best practices in pharmacy performance-based payment arrangements.

[View the webinar on-demand.](#)

GEMTESA

DISCOVER
AN ALTERNATIVE
FORMULARY
OPTION

Find out more at
GEMTESA.com

GEMTESA, and the GEMTESA logo are trademarks of Urovant Sciences GmbH, registered in the U.S. and in other countries. © 2021 Urovant Sciences. All Rights Reserved. 6/21 US-VBGN-2000113 (v2.0)


GEMTESA®
(vibegron) 75 mg
tablets